FDA Approves a 3-in-1 Combination Hypertension Drug

FDA Approves a 3-in-1 Combination Hypertension Drug: The drug Tribenzor is approved as a once-daily treatment for hypertension which combines olmesartan medoxomil, amlodipine, and hydrochlorothiazide in a single tablet. Tribenzor is approved for patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics. This new 3-in-1 drug is not approved for initial therapy. Approximately 56% of patients taking current blood pressure-lowering therapies do not reach current recommended blood pressure goals of <140/90 mm Hg or <130/80 mm Hg for patients with diabetes, chronic renal disease, or chronic cardiovascular disease. A fixed-dose combination treatment can simplify dosing regimens, reduce pill burden, and has the potential to lower co-pays for patients that require three medications. Research also shows that the use of fixed-dose antihypertensive combination treatments may improve patient compliance. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Daiichi Sankyo, Inc.